---
title: 'Zymeworks, Phathom, Catalyst, CenExel, Intercept + Advanz'
type: 'episode'
url: 'https://doc.social/episodes/zymeworks-phathom-catalyst-cenexel-intercept-advanz'
show: 'Life Science Today'
show_url: 'https://doc.social/podcasts/life-science-today'
published: '2022-05-10'
audio: 'unavailable — the host retired the file'
---

# Zymeworks, Phathom, Catalyst, CenExel, Intercept + Advanz

Resets for biotech, antibiotics approval not enough, continued consolidation, and a normal dealFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesZymeworksPhathomCatalystCenExelIntercept + AdvanzAbout the ShowLife Science To…

## Summary

Resets for biotech, antibiotics approval not enough, continued consolidation, and a normal deal

**Find out more at
**[https://LifeScienceTodayPodcast.com
](https://lifesciencetodaypodcast.com/)
**Story References
**[Zymeworks](https://www.biospace.com/article/zymeworks-mulling-733-million-bid-from-all-blue-capital/?s=79)
[Phathom](https://investors.phathompharma.com/news-releases/news-release-details/phathom-pharmaceuticals-announces-fda-approval-voqueznatm-triple)
[Catalyst](https://www.biospace.com/article/releases/catalyst-clinical-research-acquires-aptus-clinical-to-accelerate-european-expansion-broaden-client-services-and-enhance-patient-impact/?s=79)
[CenExel](https://www.biospace.com/article/releases/cenexel-acquires-iresearchpremier-cns-focused-research-facilities-in-georgia-join-the-cenexel-centers-of-excellence-clinical-research-site-network/?s=79)
[Intercept + Advanz**
**](https://www.biospace.com/article/releases/intercept-announces-advanz-pharma-to-acquire-ocaliva-in-pbc-in-markets-outside-the-u-s-for-up-to-450mm-including-405mm-upfront-and-an-additional-45mm-in-contingent-payments/?s=79)
**About the Show
**Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.